Herantis Pharma Plc (“Herantis”) will publish its Financial Statements in regard to 2019 on the 27th of February 2020. The financial reporting schedule of Herantis in 2020 is as follows:
- Financial Statements bulletin in regard to 2019 on Thursday the 27th of February 2020
- Interim Report on January-June 2020 on Thursday the 27th of August 2020
The Annual General Meeting is planned to be held on Wednesday the 8th of April 2020. The Board of Directors will present a formal notice at a later stage.
The Annual Report for 2019 will be published in electronic format on the company’s web site by the 17th of March 2020.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +46 72 888 43 83
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with ticker symbol “HRTIS” and on the Nasdaq First North Growth Market Sweden with ticker symbol “HRNTS”.